Customize your JAMA Network experience by selecting one or more topics from the list below.
Hulley S, Grady D, Bush T, et al. Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women. JAMA. 1998;280(7):605–613. doi:10.1001/jama.280.7.605
Context.— Observational studies have found lower rates of coronary heart disease
(CHD) in postmenopausal women who take estrogen than in women who do not,
but this potential benefit has not been confirmed in clinical trials.
Objective.— To determine if estrogen plus progestin therapy alters the risk for
CHD events in postmenopausal women with established coronary disease.
Design.— Randomized, blinded, placebo-controlled secondary prevention trial.
Setting.— Outpatient and community settings at 20 US clinical centers.
Participants.— A total of 2763 women with coronary disease, younger than 80 years,
and postmenopausal with an intact uterus. Mean age was 66.7 years.
Intervention.— Either 0.625 mg of conjugated equine estrogens plus 2.5 mg of medroxyprogesterone
acetate in 1 tablet daily (n=1380) or a placebo of identical appearance (n=1383).
Follow-up averaged 4.1 years; 82% of those assigned to hormone treatment were
taking it at the end of 1 year, and 75% at the end of 3 years.
Main Outcome Measures.— The primary outcome was the occurrence of nonfatal myocardial infarction
(MI) or CHD death. Secondary cardiovascular outcomes included coronary revascularization,
unstable angina, congestive heart failure, resuscitated cardiac arrest, stroke
or transient ischemic attack, and peripheral arterial disease. All-cause mortality
was also considered.
Results.— Overall, there were no significant differences between groups in the
primary outcome or in any of the secondary cardiovascular outcomes: 172 women
in the hormone group and 176 women in the placebo group had MI or CHD death
(relative hazard [RH], 0.99; 95% confidence interval [CI], 0.80-1.22). The
lack of an overall effect occurred despite a net 11% lower low-density lipoprotein
cholesterol level and 10% higher high-density lipoprotein cholesterol level
in the hormone group compared with the placebo group (each P<.001). Within the overall null effect, there was a statistically
significant time trend, with more CHD events in the hormone group than in
the placebo group in year 1 and fewer in years 4 and 5. More women in the
hormone group than in the placebo group experienced venous thromboembolic
events (34 vs 12; RH, 2.89; 95% CI, 1.50-5.58) and gallbladder disease (84
vs 62; RH, 1.38; 95% CI, 1.00-1.92). There were no significant differences
in several other end points for which power was limited, including fracture,
cancer, and total mortality (131 vs 123 deaths; RH, 1.08; 95% CI, 0.84-1.38).
Conclusions.— During an average follow-up of 4.1 years, treatment with oral conjugated
equine estrogen plus medroxyprogesterone acetate did not reduce the overall
rate of CHD events in postmenopausal women with established coronary disease.
The treatment did increase the rate of thromboembolic events and gallbladder
disease. Based on the finding of no overall cardiovascular benefit and a pattern
of early increase in risk of CHD events, we do not recommend starting this
treatment for the purpose of secondary prevention of CHD. However, given the
favorable pattern of CHD events after several years of therapy, it could be
appropriate for women already receiving this treatment to continue.
MANY OBSERVATIONAL studies have found lower rates of coronary heart
disease (CHD) in women who take postmenopausal estrogen than in women not
receiving this therapy.1-5
This association has been reported to be especially strong for secondary prevention
in women with CHD, with hormone users having 35% to 80% fewer recurrent events
If this association is causal, estrogen therapy could be an important method
for preventing CHD in postmenopausal women. However, the observed association
between estrogen therapy and reduced CHD risk might be attributable to selection
bias if women who choose to take hormones are healthier and have a more favorable
CHD profile than those who do not.13-15
Observational studies cannot resolve this uncertainty.
Only a randomized trial can establish the efficacy and safety of postmenopausal
hormone therapy for preventing CHD. The Heart and Estrogen/progestin Replacement
Study (HERS) was a randomized, double-blind, placebo-controlled trial of daily
use of conjugated equine estrogens plus medroxyprogesterone acetate (progestin)
on the combined rate of nonfatal myocardial infarction (MI) and CHD death
among postmenopausal women with coronary disease. We enrolled women with established
coronary disease because their high risk for CHD events and the strong reported
association between hormone use and risk of these events make this an important
and efficient study population in which to evaluate the effect of hormone
The design, methods, and baseline findings of the study have been published.16 Briefly, participants were postmenopausal women younger
than 80 years with established coronary disease who had not had a hysterectomy.
Postmenopausal was defined as age at least 55 years and no natural menses
for at least 5 years, or no natural menses for at least 1 year and serum follicle-stimulating
hormone (FSH) level more than 40 IU/L, or documented bilateral oophorectomy,
or reported bilateral oophorectomy with FSH level more than 40 IU/L and estradiol
level less than 92 pmol/L (25 pg/mL). Established coronary disease was defined
as evidence of 1 or more of the following: MI, coronary artery bypass graft
surgery, percutaneous coronary revascularization, or angiographic evidence
of at least a 50% occlusion of 1 or more major coronary arteries.
Women were excluded for the following reasons: CHD event within 6 months
of randomization; serum triglyceride level higher than 3.39 mmol/L (300 mg/dL);
use of oral, parenteral, vaginal, or transdermal sex hormones within 3 months
of the screening visit; history of deep vein thrombosis or pulmonary embolism;
history of breast cancer or breast examination or mammogram suggestive of
breast cancer; history of endometrial cancer; abnormal uterine bleeding, endometrial
hyperplasia, or endometrium thickness greater than 5 mm on baseline evaluation;
abnormal or unobtainable Papanicolaou test result; serum aspartate aminotransferase
level more than 1.2 times normal; unlikely to remain geographically accessible
for study visits for at least 4 years; disease (other than CHD) judged likely
to be fatal within 4 years; New York Heart Association class IV or severe
class III congestive heart failure; alcoholism or other drug abuse; uncontrolled
hypertension (diastolic blood pressure ≥105 mm Hg or systolic blood pressure ≥200
mm Hg); uncontrolled diabetes (fasting blood glucose level ≥16.7 mmol/L
[300 mg/dL]); participation in another investigational drug or device study;
less than 80% compliance with a placebo run-in prior to randomization; or
history of intolerance to hormone therapy.
At 2 baseline clinic visits we collected data on demographic characteristics,
reproductive and health history, risk factors for CHD, quality of life, and
medication use. Participants had a clinical examination, including breast
examination and pelvic examination with Papanicolaou test and endometrial
evaluation (endometrial aspiration biopsy if possible or otherwise transvaginal
ultrasound measurement of endometrial thickness), and a screening mammogram.
Standardized 12-lead electrocardiograms (ECGs) were obtained using the Mac
PC (Marquette Electronics, Milwaukee, Wis) and transmitted electronically
to EPICARE (Wake Forest University School of Medicine, Winston-Salem, NC)
where they were analyzed using computer protocols.17
Fasting total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density
lipoprotein (HDL) cholesterol, and triglyceride levels were determined by
the Lipoprotein Analytical Laboratory at Johns Hopkins Hospital.18
The randomization code was prepared using computer-generated random
numbers. Eligible participants were assigned with equal probability to the
2 treatment groups using tamper-proof blocked randomization stratified by
clinical center. At each center, women who met the entry criteria were logged
and assigned the next available sequential randomized treatment assignment.
Study medication consisted of 1 tablet daily containing both conjugated
equine estrogens, 0.625 mg, and medroxyprogesterone acetate, 2.5 mg (estrogen
plus progestin [Prempro]), or 1 placebo tablet of identical appearance. Chemical
analysis of tablets confirmed the composition of the tablets and the accuracy
of the blinded medication assignment.
With the exception of 3 persons at the Coordinating Center at the University
of California, San Francisco, who prepared analyses for the Data and Safety
Monitoring Board and for the final report, investigators and staff at the
clinical centers, Wyeth-Ayerst Research, the Coordinating Center, and the
independent Morbidity and Mortality Subcommittee were blinded to individual
participant assignment throughout the study. To prevent unblinding of clinical
center staff, breast discomfort and vaginal bleeding were reported directly
to gynecology staff who were located separate from the clinical center, did
not communicate with clinical center personnel about gynecologic symptoms,
and did not participate in ascertainment of cardiovascular outcomes. Sealed
treatment allocation envelopes were available to the study center gynecologist.
To determine if endometrial biopsy was necessary, the gynecologists could
open a treatment assignment envelope in limited, defined situations with prior
approval of a Coordinating Center physician. Unblinding in this fashion, generally
to assist in the management of persistent vaginal bleeding, occurred in 34
women (30 in the hormone group, among whom 1 primary CHD event occurred).
Follow-up visits to the clinical center occurred every 4 months to assess
and enhance compliance, provide study medication refills, and obtain outcome
and adverse event data. Annual evaluations at the clinical center included
general and cardiac examinations, an ECG, and venipuncture at the first, third,
and final annual visits. Separate annual follow-up visits to the study gynecologist
included repeat breast examination, pelvic examination with Papanicolaou test,
screening mammogram, and a repeat endometrial evaluation at the second and
final annual visits.
We used extensive quality assurance procedures for clinical management
and data collection. All procedures were defined by the Coordinating Center
in the HERS procedure manual, with formalized updates and clarifications.
The Coordinating Center monitored the degree to which procedures at the clinics
conformed with those described in the procedure manual during annual site
visits. All data were entered twice and checked by computer algorithms.
Study treatment was discontinued (but follow-up continued) for women
who developed any of the following conditions: simple endometrial hyperplasia
without atypia that did not respond to treatment with progestin; endometrial
hyperplasia with atypia; endometrial, cervical, breast, or ovarian cancer;
deep vein thrombosis; pulmonary embolism; prolonged immobilization; or active
The CHD events (nonfatal MI or CHD death) that occurred between the
date of randomization and the closeout date were the primary outcome of the
trial; nonfatal MI could be either symptomatic or silent, and CHD death could
be a fatal documented MI, sudden death within 1 hour of onset of symptoms,
unobserved death that occurred out of the hospital in the absence of other
known cause, or death due to coronary revascularization procedure or congestive
heart failure. The diagnosis of nonfatal MI was based on an algorithm16 that took into account 3 categories of clinical information
from the acute event: ischemic symptoms, ECG abnormalities, and elevated cardiac
enzyme levels. The diagnosis could also be made if there was evidence of fresh
MI at autopsy. All ECGs obtained electronically were compared with the ECG
obtained at baseline for changes indicating new MI.
Secondary cardiovascular outcomes included coronary artery bypass graft
surgery, percutaneous coronary revascularization, hospitalization for unstable
angina, resuscitated cardiac arrest, congestive heart failure, stroke or transient
ischemic attack, and peripheral arterial disease. Other prespecified secondary
outcomes were total mortality; cancer death; non-CHD, noncancer death; breast,
endometrial, and other cancer; deep vein thrombosis; pulmonary embolism; hip
and other fracture; and gallbladder disease.16
The primary and secondary outcomes of HERS were addressed at each follow-up
contact. Suspected outcome events were reported within 24 hours to the Coordinating
Center, which had primary responsibility for the outcome database, and to
Wyeth-Ayerst Research as a cross-check. Clinics obtained and sent to the Coordinating
Center specified documentation that included (depending on the suspected event)
hospital discharge summaries, ECGs, cardiac enzyme levels and other test results,
and reports of tissue pathology, procedures, and x-ray examinations. Data
from all deaths and suspected primary outcome events were reviewed and classified
according to prespecified criteria by an independent Morbidity and Mortality
Subcommittee blinded to treatment assignment. Secondary events were classified
by Coordinating Center physicians blinded to treatment assignment. Every event
(whether primary or secondary) was classified independently by 2 reviewers,
and discordant classifications were resolved in discussions between the reviewers.
Problematic potential primary events were discussed on conference calls or
meetings involving the entire subcommittee.
Vital status is known for all 2763 women, and all deaths are included
in this report. We are still in the process of collecting hospital records
and adjudicating recent events. Included in this report are 99% of all primary
CHD events reported to have occurred by the closeout visit (April-July 1998)
and 97% of all secondary events. Adjudication is final for 96% of included
primary events (the remaining classifications are provisional), and it is
final for 99% of included secondary events.
We estimated that we needed to enroll 2340 women, assuming a primary
CHD event rate in the placebo group of 5% per year, a combined non-CHD death
and loss to follow-up rate of 2% per year, crossovers from active to placebo
of 5%, 4%, and 3% in the first 3 years and 2% per year thereafter, crossovers
from placebo to active of 1% each year, and average follow-up of 4.75 years.16 We assumed that half the reduction in primary CHD
events would operate through nonlipid mechanisms (and therefore be immediate),
and half would operate through lipid changes (and therefore begin after a
2-year lag period). These assumptions resulted in 90% power at a 2-tailed α
of .05 to detect an intention-to-treat effect size of 24%. In the actual study,
the event rate was only 3.3%, compliance was less than expected, and treatment
duration averaged 4.1 years. The chief reason for the shorter-than-expected
treatment duration, despite ending the study at the planned time, was the
fact that most women were enrolled toward the end of the recruitment period.
The reduction in power caused by these deviations from prestudy assumptions
was partially offset by the fact that we recruited 18% more participants than
The primary analysis compares the rate of CHD events among women assigned
to active medication with the rate among women assigned to placebo using an
unadjusted Cox proportional hazards model for time to first CHD event; this
is equivalent to the log rank test. The analysis was by intention to treat,
categorizing participants according to randomized treatment assignment regardless
of compliance. Participants who asked to drop out of the study and had not
had a nonfatal MI were censored for nonfatal events at their last visit (this
occurred for 31 women in the hormone group and 38 women in the placebo group);
however, vital status was assessed at the end of the trial for 100% of the
cohort, and all deaths are included in this report.
Secondary analyses used multivariate proportional hazards models to
investigate study findings. Possible confounding was examined by controlling
for important baseline covariates. To identify potential postrandomization
confounders, treatment effect estimates were compared in nested models with
and without measures of postrandomization lipid-lowering drug use and lipid
change. These covariates were also included in an as-treated model, where
inclusion in the risk sets was limited to women in both treatment groups whose
average pill-count compliance since randomization was at least 80%; this model
included 74% of the primary events. Relative hazards were estimated by year
since randomization (censoring women with events in earlier years), and continuous
trend in the log relative hazard was examined in a companion model. Time-dependent
indicators were used to assess risk by treatment assignment among women who
had recently stopped taking study medication.
Interim monitoring of study events every 3 to 6 months was performed
by an independent HERS Data and Safety Monitoring Board. Early in the trial
the board noted adverse trends in primary CHD events, which conflicted with
existing evidence and did not cross the stopping boundaries.19
In the middle years of the trial, an increased risk of venous thromboembolic
events in the hormone-treated group consistent with existing evidence did
cross the stopping boundaries. As a consequence, the board advised HERS investigators
to report the findings regarding increased risk of venous thrombosis and to
institute additional measures to reduce risk in HERS participants.20 Near the end of the trial, the board noted a trend
toward lower rates of nonfatal MI in the hormone group. At its final meeting
in December 1997, the board recommended against continuing the study beyond
the scheduled closeout date, because at that time conditional power estimates
for primary CHD events were low and because of uncertainty about whether a
sufficient proportion of women would consent to continue blinded treatment.
The board recommended closeout at the originally planned time (April-July
1998), continuation of disease event surveillance, and rapid publication of
the findings to allow HERS participants to make timely informed decisions
concerning their use of this specific hormone therapy.
Between January 1993 and September 1994, the 20 HERS clinical centers
enrolled 2763 women; 1380 were assigned to the hormone group and 1383 to the
placebo group (Figure 1). Participants
ranged in age from 44 to 79 years, with a mean of 66.7 years (SD, 6.7 years)
at baseline. Most participants were white (89%) and had completed high school
(80%). Examination of the distribution of these and other variables revealed
no significant differences between the treatment groups at baseline (Table 1).
At the end of the first year, the proportion who reported taking study
medication was 82% in the hormone group and 91% in the placebo group; by the
end of the third year, these proportions had declined to 75% and 81%. Pill
counts revealed 79% of the women in the hormone group to be taking at least
80% of their study medication at the end of year 1 and 70% to be doing so
at the end of year 3 (Figure 2).
Among women who stopped taking HERS medications, 110 (8%) of those assigned
to the placebo group and 36 (3%) of those assigned to the hormone group reported
taking open-label oral or transdermal estrogen.
During the closeout period (April-July 1998), vital status was ascertained
for all 2763 randomized women. Follow-up percentages were nearly the same
in the 2 randomized groups (Figure 1).
Primary CHD events occurred in 172 women in the hormone group (33.1/1000
women per year) and in 176 women in the placebo group (33.6/1000 women per
year) (relative hazard [RH], 0.99; 95% confidence interval [CI], 0.80-1.22)
(Table 2). These primary events
were composed of CHD deaths (RH, 1.24; 95% CI, 0.87-1.75) and nonfatal MIs
(RH, 0.91; 95% CI, 0.71-1.17). None of these differences was statistically
significant. The 71 CHD deaths in the hormone group and the 58 CHD deaths
in the placebo group were distributed, respectively, as follows: sudden death
within 1 hour of onset of symptoms, 19 and 20; myocardial infarction, 19 and
16; congestive heart failure, 9 and 6; coronary artery bypass graft surgery,
5 and 2; and other CHD death, 19 and 14.
Survival curves for the primary CHD outcome and its components (Figure 3) correspond with the findings in Table 2. The curves for CHD death diverged
during the second year of observation. The curves for nonfatal MI diverged
during the first year, then converged and crossed during the third year. This
possible change in the RH with time since randomization is further examined
in Table 3. The point estimates
for the primary outcome in the hormone group compared with the placebo group
are 1.52 in year 1, 1.00 in year 2, 0.87 in year 3, and 0.67 in years 4 and
5 (P=.009 for trend in log RH); within the first
year, the RH was 2.30 for the first 4 months, 1.46 for the second 4 months,
and 1.18 for the third 4 months (P=.33 for trend).
The difference over time was most pronounced for the nonfatal MI component
of the primary CHD outcome (Table 3
and Figure 3).
In an as-treated analysis limited to women who had been at least 80%
compliant with study medication by pill count, the RH comparing the primary
CHD outcome in the hormone and placebo groups was 0.87 (95% CI, 0.67-1.11),
lower than the intention-to-treat analysis but not statistically significant.
For women who stopped taking HERS medication, risk of primary CHD events was
elevated in the first month after stopping use of the medication. However,
there was no difference by group (RH in hormone group, 7.28; 95% CI, 4.45-11.93;
RH in placebo group, 7.40; 95% CI, 4.23-12.95), suggesting that illness caused
both the discontinuation of medication and the CHD event.
The RH comparing risk of the primary CHD outcome in the hormone and
placebo groups was similar after adjusting for the small and nonsignificant
differences between the groups in age and other baseline CHD risk factors
(RH, 0.95; 95% CI, 0.76-1.17). We sought to identify differential effects
of estrogen plus progestin therapy in women classified by baseline variables
such as older age, ill health, history of MI, and so forth. There was no clear
evidence of differential effects in 86 subgroups categorized by all the variables
presented in Table 1 and others.
There were no statistically significant differences between the randomized
groups in any of the other cardiovascular outcomes that we evaluated (Table 2). The survival curve for time to
first occurrence of any coronary revascularization procedure or hospitalization
for definite unstable angina (Figure 4)
appeared to diverge, with lower rates in the hormone-treated group, although
this difference did not achieve statistical significance (RH, 0.89; P =.15).
By the end of the first year of treatment, mean LDL cholesterol levels
had decreased by 14% from baseline to a level of 3.23 mmol/L (125 mg/dL) in
the hormone group and by 3% to 3.62 mmol/L (140 mg/dL) in the placebo group
(P<.001 for difference between groups) (Figure 5). During the same period, mean HDL
cholesterol levels had increased by 8% to 1.40 mmol/L (54 mg/dL) in the hormone
group and decreased by 2% to 1.27 mmol/L (49 mg/dL) in the placebo group (p<.001).
Mean triglyceride levels had increased by 10% to 2.04 mmol/L (181 mg/dL) in
the hormone group and by 2% to 1.93 (170 mg/dL) in the placebo group (P<.001).
In proportional hazards analysis, high LDL cholesterol and low HDL cholesterol
levels at baseline predicted subsequent primary CHD events in both univariate
and multivariate (controlling for other baseline risk factors) models, but
high triglyceride levels predicted primary CHD events only in univariate analyses.
Changes in LDL cholesterol, HDL cholesterol, and triglyceride levels over
the first year of the study were not significantly associated with subsequent
primary CHD events, but the point estimates were in the expected direction
and there was limited power to examine this effect.
More women in the placebo group than in the hormone group began treatment
with lipid-lowering drugs, primarily statins, during the trial (22% vs 18%; P=.004), probably because the higher LDL cholesterol levels
in placebo-treated women compared with hormone-treated women were noted by
the women's personal physicians. Adjustment for this difference using regression
analysis did not substantially change the overall estimate of the between-group
difference in risk of primary CHD events (RH, 0.94; 95% CI, 0.76-1.17).
Cancer deaths and other deaths were nearly identical in the 2 study
groups. Total mortality in the hormone group was not significantly different
from that in the placebo group (131 vs 123 women; RH, 1.08; 95% CI, 0.84-1.38)
(Table 4; Figure 6).
Confirmed venous thromboembolic events occurred in 34 women in the hormone
group (6.3/1000 woman-years) and in 12 women in the placebo group (2.2/1000
woman-years) (RH, 2.89; 95% CI, 1.50-5.58; P =.002)
(Table 4). More women in the hormone
group experienced deep vein thromboses (25 vs 8; P
=.004) and pulmonary emboli (11 vs 4; P =.08); 2
of the pulmonary emboli, both in the hormone group, were fatal. The RH in
the hormone group relative to the placebo group remained elevated over the
4 years of observation but declined somewhat during the study (Table 3).
Gallbladder disease occurred in 84 women in the hormone group and in
62 women in the placebo group (RH, 1.38; 95% CI, 1.00-1.92). Gallbladder surgery
accounted for 89% of these events, and the rest were symptomatic cholelithiasis.
None of the gallbladder events was fatal.
There were no significant differences between the treatment groups in
the rates of breast cancer, endometrial cancer, other cancers, or fracture
In this clinical trial, postmenopausal women younger than 80 years with
established coronary disease who received estrogen plus progestin did not
experience a reduction in overall risk of nonfatal MI and CHD death or of
other cardiovascular outcomes. How can this finding be reconciled with the
large body of evidence from observational and pathophysiologic studies suggesting
that estrogen therapy reduces risk for CHD?
Observational studies may be misleading because women who take postmenopausal
hormones tend to have a better CHD risk profile13,21,22
and to obtain more preventive care14 than nonusers.
The consistency of the apparent benefit in the observational studies could
simply be attributable to the consistency of this selection bias. The lower
rate of CHD in hormone users compared with nonusers persists after statistical
adjustment for differences in CHD risk factors,22
but differences in unmeasured factors remain a possible explanation.
The discrepancy between the findings of HERS and the observational studies
may also reflect important differences between the study populations and treatments.
Most of the observational studies of postmenopausal hormone therapy enrolled
postmenopausal women who were relatively young and healthy and who took unopposed
In contrast, participants in HERS were older, had coronary disease at the
outset, and were treated with estrogen plus progestin. However, some observational
studies did examine women with prior CHD, and all of these reported a beneficial
association with postmenopausal hormone therapy.6-12
Similarly, some observational studies did examine the effect of postmenopausal
estrogen plus progestin therapy on CHD risk in women, and these generally
report a lower rate of CHD events in hormone users that is similar to that
reported for estrogen alone4,5,22,24-27;
however, details in these studies about the specific progestin formulations
and dosing regimens used are limited.
Several potential mechanisms whereby estrogen therapy might reduce risk
for CHD have been proposed, including favorable effects on lipoproteins, coronary
atherosclerosis, endothelial function, and arterial thrombosis.28,29
Progestins down-regulate estrogen receptors and may also have direct, progestin
receptor–mediated effects that oppose these actions of estrogen30; medroxyprogesterone acetate may do this to a greater
extent than other progestins. In the Postmenopausal Estrogen-Progestin Interventions
Trial, medroxyprogesterone acetate blunted the estrogen-associated increase
in HDL cholesterol substantially more than did micronized progesterone.31 Oral medroxyprogesterone acetate appears to significantly
attenuate the beneficial effects of estrogen on coronary atherosclerosis in
nonhuman primates,32 while subcutaneous progesterone
does not.33 Animal data also suggest that medroxyprogesterone
acetate may inhibit the beneficial effects of estrogen on endothelial-dependent
vasodilation,34 but this has not been documented
in women.35 Despite these mechanistic data
suggesting an adverse effect of medroxyprogesterone acetate, observational
studies show a similar reduction in CHD risk in women using medroxyprogesterone
acetate plus estrogen as in women taking unopposed estrogen.4
When the results were examined by year since randomization, the estrogen
plus progestin regimen appeared to increase risk for primary CHD events in
the first year of therapy but to decrease risk in subsequent years. This time
trend should be interpreted with caution. It could simply represent random
variation, although the level of statistical significance makes this unlikely.
More importantly, between-group contrasts that exclude the first several years
are not true randomized comparisons, as the remaining study groups may no
longer be comparable if, for example, treatment has caused high-risk individuals
to have events early in the study.
On the other hand, the time trend is biologically plausible. The early
increase in risk for CHD events might be attributable to an immediate prothrombotic,
proarrhythmic, or proischemic effect of treatment that is gradually outweighed
by a beneficial effect on the underlying progression of atherosclerosis, perhaps
as a result of beneficial changes in lipoproteins. In trials of lipid interventions,
the delay before CHD risk is reduced has ranged from 0 to 2 years.36-41
After a lag period, the 11% net reduction in LDL cholesterol and 10% net increase
in HDL cholesterol observed in the hormone group would be expected to reduce
the risk of CHD events36,42 and
may account for the trend toward a late benefit observed in HERS.
A pattern of early harm and later benefit could account for part of
the discrepancy between the results of this trial and observational studies
of estrogen and CHD. Attrition of susceptible individuals soon after starting
estrogen replacement could increase the prevalence of survivors available
for inclusion in observational studies; most observational studies are not
designed to observe the onset of therapy or to detect an early adverse effect.
The CHD data from previous hormone trials in women have been summarized43 but are of limited value because the studies were
small, short term, and not designed to examine CHD as an outcome. The only
large prior trial of estrogen therapy to prevent CHD events was the Coronary
Drug Project, which studied very high doses of estrogen (5.0 mg or 2.5 mg
of conjugated equine estrogen daily) in men with preexisting CHD. The estrogen
arms of this trial were stopped early because of an excess of MIs, thromboembolic
events, and estrogenic symptoms in the 5.0-mg/d group44
and the lack of benefit on the CHD end point and estrogenic symptoms in the
2.5-mg/d group.45 The relevance of this trial
of high-dose estrogen in men to postmenopausal hormone therapy in women is
Venous thromboembolic events were 3 times more common in the hormone
group than in the placebo group. Recent observational studies have reported
similar relative risks for idiopathic venous thromboembolism among users of
both unopposed estrogen46-49
and estrogen plus progestin therapy.47,49
The excess incidence of venous thrombotic events in HERS was 4.1 per 1000
woman-years of observation, an order of magnitude higher than the excess reported
in the observational studies; the higher rate is probably a consequence of
the facts that women enrolled in HERS were older and had multiple risk factors
for venous thrombosis and that only idiopathic events were counted in the
We found an increased risk of gallbladder disease in the hormone group
that is likely attributable to the estrogen therapy. Metabolic studies indicate
that estrogen enhances hepatic lipoprotein uptake and inhibits bile acid synthesis,
resulting in increased biliary cholesterol and cholelithiasis.50
Observational studies have suggested that therapy with postmenopausal
estrogen for 5 years or less is not associated with an increased risk of breast
cancer but that longer duration of therapy might be associated with a small
increase in risk.51 The HERS trial was not
large enough and therapy did not continue for long enough to address this
The incidence of fractures in the hormone group was only slightly lower
than in the placebo group. Wide CIs around the fracture risk estimates reveal
inadequate statistical power and do not exclude a reduction in risk of hip
fracture of as much as 51% or a reduction in risk of other fracture of as
much as 27%.
The CHD risk factor profile of women enrolled in HERS is similar to
that of a random sample of US women with probable heart disease, suggesting
that the findings of HERS may be generalized to that population.52
However, HERS did not evaluate the effect of estrogen plus progestin therapy
in women without CHD, and it is not known whether our findings apply to healthy
women. It is also not known whether use of a different progestin or of estrogen
alone would have been beneficial.
HERS exceeded the recruitment goal by 18%, carried out a successful
randomization, collected objective, blindly adjudicated disease outcome data,
and achieved 100% vital status ascertainment. Compliance with hormone treatment,
while lower than projected, was sufficient to produce LDL and HDL cholesterol
changes that compare favorably with previous studies.31
The 95% CIs for the effect of treatment assignment on primary CHD events (RH,
0.99; 95% CI, 0.80-1.22) make it unlikely that HERS missed a benefit of more
than 20% for the overall 4.1-year period of observation. However, this statistic
does not address the possible late benefit of treatment suggested by the time
trend analysis, which is plausible based on the finding of a 1- to 2-year
lag period observed in lipid trials36-41;
a longer study would be more definitive for investigating this possibility.
HERS is the first large trial of the effect of postmenopausal estrogen
plus progestin therapy on risk for CHD events. The findings differ from those
of observational studies and studies with surrogate outcomes, emphasizing
the importance of basing treatment policies on randomized controlled trials.53 Other randomized trials of postmenopausal hormone
therapy are likely to answer some of the questions raised by HERS. The Women's
Health Initiative Randomized Trial54 includes
a group of women who have undergone hysterectomy and receive unopposed estrogen
as well as women with intact uterus who receive the same estrogen plus progestin
regimen used in HERS. Participants are not required to have CHD and are generally
younger than the HERS cohort. The Women's Health Initiative Randomized Trial
plans to enroll 27500 women and to report the results in 2005 after 9 years
of treatment. Further information will also emerge from HERS as we continue
disease event surveillance.
Several interventions have been proven to reduce risk for CHD events
in patients with coronary disease, including aspirin, β-blockers, lipid
lowering, and smoking cessation.55 The need
for encouraging these interventions for women with coronary disease is illustrated
by the facts that 90% of the HERS cohort had LDL cholesterol exceeding 2.59
mmol/L (100 mg/dL) at baseline and that only 32% were receiving β-blockers.
First, in the population studied in HERS, ie, postmenopausal women with
established coronary disease and an average age of 66.7 years, daily use of
conjugated equine estrogens and medroxyprogesterone acetate did not reduce
the overall risk for MI and CHD death or any other cardiovascular outcome
during an average of 4.1 years of follow-up. This therapy did increase the
risk of venous thromboembolic events and gallbladder disease.
Second, we did not evaluate the cardiovascular effect of treatment with
unopposed estrogen, commonly used in women who have had a hysterectomy, or
other estrogen plus progestin formulations. We also did not study women without
Third, based on the finding of no overall cardiovascular benefit and
a pattern of early increase in risk of CHD events, we do not recommend starting
this treatment for the purpose of secondary prevention of CHD. However, given
the favorable pattern of CHD events after several years of therapy, it could
be appropriate for women already receiving hormone treatment to continue.
Extended follow-up of the HERS cohort and additional randomized trials are
needed to clarify the cardiovascular effects of postmenopausal hormone therapy.
Create a personal account or sign in to: